Main > > >KIDNEY CANCER. *

---

Renal Cell Carcinoma (RCC). Treat.:
Aldesleukin>(Recombinant IL-2) for Inj.
(METASTATIC)
USA Approval Year: 1992.
(*) Company : Clinigen Group Ltd.
Patent : Expired
TradeMark: Proleukin
Web-Site : www.proleukin.com
UpDate: 2019. 02.14.




Renal Cell Carcinoma (RCC). Treat.:
AveluMAb+Axitinib. (METASTATIC)
EU Approval Date : 2019. 10.28.
USA Approval Date: 2019. 05.15.
(*) Companies; TradeMarks; USA Patent
APPs. & Web-Sites Available on
Request.
UpDate: 2019. 12.31.




Renal Cell Carcinoma (RCC). Treat.:
Axitinib. (METASTATIC)
USA Approval Date: 2012. 06.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.05.




Renal Cell Carcinoma (RCC). Treat.:
BevacizuMAb BioSimilar+Interferon Alfa
(METASTATIC)
USA Approval Date: 2017. 09.14.
USA Launch Date: 2019. 07.18.
(*) Company : Amgen
TradeMark: Mvasi
UpDate: 2019. 11.12.




Renal Cell Carcinoma (RCC). Treat.:
BevacizuMAb BioSimilar+Interferon Alfa
(METASTATIC)
EU Approval Date : 2019. 02.19.
USA Approval Date: 2019. 06.28.
(*) Company : Pfizer
TradeMark: ZIRABEV
UpDate: 2020. 01.08.




Renal Cell Carcinoma (RCC). Treat.:
Cabozantinib Tablets. (METASTATIC).
Mechanism>Tyrosine Kinases Inh.>AXL, MET
VEGFR-1,2 & 3
CA Approval Date: 2018. 09.19.
EU Approval Date: 2016. 09.09.>
JP Approval Date: 2020. 03.25.
>previously received anti-angiogenic
therapy
EU Approval Date: 2018. 05.17.>
>Previously Untreated First Line Treat.
USA Approval Date: 2016. 04.25.>
>previously received anti-angiogenic
therapy
USA Approval Date: 2017. 12.20>
>Previously Untreated First Line Treat.
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.26.




Renal Cell Carcinoma (RCC). Treat.:
Cabozantinib Tablets+NivoluMAb.
(RCC>Advanced>1st Line Treat.)
USA Approval Date: 2021. 01.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.15.




Renal Cell Carcinoma (RCC). Treat.: CryoAblation System.
IL>Being Used at IL Hospital.
USA>Approval Date: 2020. 01.07.
Surgery-Free Technology.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.10.




Renal Cell Carcinoma (RCC). Treat.:
Embolization. 500 Embolization Biode- gradable MicroSpheres Detectable by UltraSound.
CA Approval Date : 2018. 11.21.
USA Approval Date: ?
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.25.




Renal Cell Carcinoma (RCC). Treat.: Eve-
rolimus Tablets. (METASTATIC).
When Sorafenib &/or Sunitinib have not
worked.
Mechanism: mTOR Kinase Inhibition.
EU Approval Date : 2009. 08.11.
USA Approval Date: 2009. 03.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request
UpDate: 2018. 11.23.




Renal Cell Carcinoma (RCC). Treat.:
IpilimuMAb+NivoluMAb (METASTATIC)
EU Approval Date: 2019. 01.14.
(*) Company; TradeMarks & Web-Site
Available on Request.
UpDate: 2019. 01.15.




Renal Cell Carcinoma (RCC). Treat.:
NivoluMAb. (METASTATIC).
Mechanism: PD-1 Inhibitor.
USA Approval Date: 2015. 11.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.16.




Renal Cell Carcinoma (RCC). Treat.: Pa- zopanib Tablets 200 mg. (METASTATIC).
(*) Company : Novartis.
TradeMark: Votrient
UpDate: 2018. 10.04.




Renal Cell Carcinoma (RCC). Treat.:
PembrolizuMAb+Axitinib. (METASTATIC)
EU Approval Date: 2019. 09.04.
JP Approval Date: 2019. 12.20.
USA Approval Date: 2019. 04.22.
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2020. 01.01.




Renal Cell Carcinoma (RCC). Treat.:
Sorafenib. (METASTATIC)
(*) Company : Bayer.
Patent : Expired.
TradeMark: Nexavar.
Web-Site : www.nexavar.com/home/
UpDate: 2018. 10.04.




Renal Cell Carcinoma (RCC). PostSurgery.
Recurrence. Prevention: Sunitinib.
USA Approval Date: 2017. 11.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.05.




Renal Cell Carcinoma (RCC). Treat.:
Sunitinib. (METASTATIC).
JP Approval Date : 2008. 04.21.
USA Approval Date: 2006. 01.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.05.




Renal Cell Carcinoma (RCC). Treat.:
TemSirolimus. (METASTATIC).
Mechanism: mTOR KInase Inhibition.
EU Approval Date : 2007. 11.19.
USA Approval Date: 2007. 05.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.05.




Renal Cell Carcinoma (RCC). Treat.:
Tivozanib. (METASTATIC)
Companion Diagnostics> ..
Mechanism: VEGF Inhibition
EU Approval Date : 2017. 08.28.
EU Launch Date : 2017. 11.15.
USA Approval Date: 2021. 03.10.
USA Launch Date: 2021. 03.22.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2021. 03.23.


>KIDNEY CANCER. *'s products
This section has no products